Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Tremelimumab Monotherapy in Unresectable Malignant Mesothelioma (Second-Line)
2008-005171-95Phase 2Completed
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- Sep 2008
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab in pleural mesothelioma and mesothelioma, sponsored by Azienda Ospedaliera Universitaria Senese. Primary endpoint: Objective response rate (ORR). Started Sep 2008; status: completed.
02
Drugs
tremelimumab
03
Conditions
pleural mesotheliomamesothelioma
Beyond the preview
Go deeper on 2008-005171-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005171-95.